CA-SCIENTIST.COM
11.7.2024 13:56:27 CEST | Business Wire | Press release
BioPharmCatalyst (BPC), a division of Scientist.com, today announced that members with an “Elite” and “Elite Plus” subscription now get full access to Trial Insights, which curates and enriches publicly available data from clinicaltrials.gov and other data sources. Trial Insights creates filterable, customizable dashboards on clinical trial status, sponsors and new medicines, enabling investors to make smarter, data-driven decisions.
“The ability to track drugs throughout their development cycle based on catalyst events not only drives biotech investor decision making, but also helps scientists keep up to date with clinical trials in their research areas,” stated John Gagliano, Senior Director, BioPharmCatalyst. “The addition of Trial Insights provides subscribers with real time insight into clinical trial results that were previously difficult and time consuming to gather through publicly available sources.”
BPC equips investors in the biotech and pharmaceutical industries with a comprehensive suite of tools for making informed investment decisions. These include an FDA calendar, a PDUFA calendar, an earnings calendar, the latest IPO information and a company’s cash database. With Trial Insights, Elite and Elite Plus subscribers can closely monitor ongoing clinical trials being conducted around the world in real time through their existing account.
To access BioPharmCatalyst’s investing tools and start a free trial, visit www.biopharmcatalyst.com. To learn more about Trial Insights, visit www.biopharmcatalyst.com/trial-insights.
About Scientist.com
Scientist.com is the world's leading AI-enabled marketplace for scientific research. The marketplace simplifies drug discovery research, saving time and money and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 100 biotechnology companies and the US National Institutes of Health (NIH).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711495417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
STARTEEPO Increases Xerox Position to 8.8 Million Shares, Becomes Second-Largest Common Shareholder14.7.2026 13:00:00 CEST | Press release
STARTEEPO Invest (“STARTEEPO”), a Prague-based alternative investment fund focused on high-conviction public equity investments, today announced that it has increased its beneficial ownership position in Xerox Holdings Corporation (“Xerox” or the “Company”) to 8.8 million common shares, together with options on an additional 140,000 shares, as disclosed in an amended Schedule 13D filing with the U.S. Securities and Exchange Commission. Based on publicly available ownership disclosures, STARTEEPO is now Xerox’s second-largest holder of common stock. “We have reached the target ownership level established for the current phase of our investment strategy,” said Frantisek Bostl, Chairman of the Board of STARTEEPO Invest. STARTEEPO’s investment thesis remains centered on balance sheet improvement, disciplined capital allocation, operational execution, the successful integration of Lexmark, and what we believe is the market’s continued undervaluation of Xerox’s long-term strategic positionin
Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 11:00:00 CEST | Press release
Renewable power, heat reuse and local data requirements are reshaping private and hybrid cloud choices, ISG Provider Lens® report says Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilien
European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 11:00:00 CEST | Press release
ERBITUX in combination with encorafenib and FOLFOX is the first and only approved targeted regimen for the first-line treatment of adult patients with BRAF V600E-mutant mCRCThe approval is based on the pivotal Phase 3 BREAKWATER trial, which demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy with or without bevacizumabERBITUX confirms its status as the pioneering anti-EGFR therapy in mCRC, now approved across different patient populations and multiple lines of therapyNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination
Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 09:58:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in
Samsung Becomes a Sisvel Wi-Fi Multimode Pool Licensee and Licensor14.7.2026 09:09:00 CEST | Press release
Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme. The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering. Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus. The agreement announced today ends litigation in the Eastern District of Texas between Samsung Elec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom